2009-015077-12: The use of corticosteroids (Budenofalk) as a chemopreventative agent in ulcerative colitis associated neoplasia |
|
|
| Ongoing | 4 | 50 | Europe | Budenofalk rectal foam, Budenofalk 2mg rectal foam, Budenofalk 2mg rectal foam | University Hospital Birmingham NHS Foundation Trust | chronic ulcerative colitis | | | | |
NCT05976802: Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis |
|
|
| Not yet recruiting | 4 | 100 | NA | High dose budesonide rectal foam, Low dose budesonide rectal foam, Matching placebo rectal foam | Bausch Health Americas, Inc. | Ulcerative Colitis | 06/25 | 06/25 | | |
2016-001921-15: Novel budesonide suppository vs. budesonide foam in acute ulcerative proctitis. |
|
|
| Ongoing | 3 | 576 | Europe | Budenofalk® suppositories (BUS), Budenofalk® 2 mg foam, Suppository, Rectal foam, Budenofalk® 2 mg foam | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH | Acute Ulcerative Proctitis, Acute Ulcerative Proctitis - Inflammation of the Rectum, Diseases [C] - Digestive System Diseases [C06] | | | | |